Max discusses the troubling trajectory of Alzheimer's drug trials, highlighting the dismal success rate of 99.6%. He explains the controversial approval of a drug aimed at reducing amyloid plaques, which failed to show any meaningful cognitive improvement despite clearing plaques from the brain. The conversation dives into the implications of such approvals and the broader issues within neurodegenerative disease research.
